Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a

IDCases

Mohamad Mooty¹  Nouran M. Salem²  Maria-Fernanda Bonilla³  Rania M. El-Lababidi⁴ 

[1] Corresponding author.;Department of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates;Department of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, p.o. box 112412, United Arab Emirates;Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Al Maryah Island, p.o. box 112412, Abu Dhabi, United Arab Emirates;

关键词: Coronavirus disease 2019;    Pegylated interferon alfa 2a;    Interferons;    SARS-CoV-2;   

DOI  :  

来源: DOAJ

【 摘 要 】

The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.

【 授权许可】

Unknown